Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
Clinical trial NCT02603120 · COMPLETED
Trial details
- NCT number
- NCT02603120
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-11
- Primary completion
- 2017-05-09
- Enrollment
- 567
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.